Related Experiment Video
Updated: Jul 17, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Delayed hypercoagulable state in COVID-19 adolescent patient: a case report
Desdiani Desdiani1,2, Nita Yulianti3, Anindita Basuki4
1Faculty of Medicine Universitas Sultan Ageng Tirtayasa Cilegon Indonesia.
Abstract:
Coronavirus disease 2019 (COVID-19) is a systemic hyperinflammation disease which can cause severe respiratory symptoms and extrapulmonary manifestations. Hypercoagulable state in COVID-19 adolescent patient is a rare case. We present the case of a 16-year-old Indonesian boy with mild COVID-19 symptoms. Initially, the patient was treated with azithromycin, N-acetyl cysteine, etc. After several days of the treatment, there was clinical improvement. However, on day 15, the patient experienced hypercoagulation and stroke-like symptoms. The patient was then subjected to additional drugs, including low-molecular weight heparin (LMWH), and peripheral neuropathy vitamin therapy. On day 20, the clinical symptoms reduced. This case demonstrates the need for further study of the association between COVID-19 and stroke in young population and the use of anticoagulants to prevent thrombotic events.
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

